EIN 26-3160079

Foundation for Angelman Syndrome Therapeutics

IRS 501(c) type
501(c)(3)
Num. employees
8
City
State
Year formed
2008
Most recent tax filings
2022-12-01
Description
Fast funds research, education, and advocacy to find a cure for Angelman Syndrome and related disorders. Based in Austin, TX.
Also known as...
Cureangelman-Org; FAST and Also
Total revenues
$52,477,819
2022
Total expenses
$8,933,021
2022
Total assets
$63,075,354
2022
Num. employees
8
2022

Program areas at Foundation for Angelman Syndrome Therapeutics

Fast's primary goal is to advance research leading to a cure for as in the form of providing grants to universities to perform research and testing.
As is a rare disorder. The community of parents and caregivers of individuals with as rely heavily on social networking to become informed and seek advice and guidance on the challenges which the disorder presents. It is one of fast's objectives to educate, support, and strengthen this community.

Grants made by Foundation for Angelman Syndrome Therapeutics

GranteeGrant descriptionAmount
Yale UniversityGeneration and Characterization of A New As Mouse Model That Recapitulates the Large Deletion of Human 15q11-q13 and A Control Line That Carries A Deletion of All Genes in 15q11-q13 But Ube3a$233,299
University of Pennsylvania (Penn)A. the Ube3a Antisense Transcript (Ube3A-As) Is A Long Non-Coding Mrna That Silences Expression of the Paternal Ube3a Gene in Neurons. Interruption of This Imprinting Phenomenon Can Be Done Through Asos, Crispr-Grna Or Other Technologies Like Microrna (Mirna). This Project Is Aiming To Develop A Strategy To Suppress the Ube3A-As in the Mouse Model of As Using Mirnas. Advantages To Mirna Are That They Are Subject To Endogenous Cellular Processing and Regulation, Which Can Help Circumvent Issues Related To Overexpression of Exogenous Genetic Material (With Ube3a Replacement), and the Need for Repeated Redosing (With Asos). Mirna Is Thought To Be Advantageous Over Shrna Due To Endogenous Cellular Processing and Regulation Compared To Overexpression You Could Get With Shrna.$115,121

Who funds Foundation for Angelman Syndrome Therapeutics

Grants from foundations and other nonprofits
GrantmakerDescriptionAmount
Fidelity Investments Charitable Gift FundFor Grant Recipient's Exempt Purposes$69,348
American Online Giving FoundationGeneral Support$26,609
Morgan Stanley Global Impact Funding TrustUnrestricted General Support$25,000
...and 17 more grants received

Personnel at Foundation for Angelman Syndrome Therapeutics

NameTitleCompensation
Alana NewhousePresident and Chief Executive Officer$50,000
Kena RichertChief Financial Officer and Treasurer / Treasurer and Cheif Financial Officer$188,000
Megan CrossDirector / Chief Information Officer / Communications Officer$0
Allyson BerentChief Science Officer$0
Maiddy DuniganFormer Officer and Chief Operating Officer / Vice Chairperson and Chief Executive Officer$104,167
...and 6 more key personnel

Financials for Foundation for Angelman Syndrome Therapeutics

RevenuesFYE 12/2022
Total grants, contributions, etc.$4,948,249
Program services$355,507
Investment income and dividends$508,992
Tax-exempt bond proceeds$0
Royalty revenue$0
Net rental income$0
Net gain from sale of non-inventory assets$47,271,158
Net income from fundraising events$-606,087
Net income from gaming activities$0
Net income from sales of inventory$0
Miscellaneous revenues$0
Total revenues$52,477,819

Form 990s for Foundation for Angelman Syndrome Therapeutics

Fiscal year endingDate received by IRSFormPDF link
2022-122023-11-15990View PDF
2021-122022-11-15990View PDF
2020-122021-10-15990View PDF
2019-122021-02-17990View PDF
2018-122020-01-28990View PDF
...and 10 more Form 990s
Data update history
January 19, 2024
Posted financials
Added Form 990 for fiscal year 2022
January 18, 2024
Updated personnel
Identified 2 new personnel
December 29, 2023
Used new vendors
Identified 2 new vendors, including , and
November 26, 2023
Received grants
Identified 5 new grant, including a grant for $25,000 from RJS Family Foundation
July 16, 2023
Posted financials
Added Form 990 for fiscal year 2021
Nonprofit Types
Grantmaking organizationsDisease research fundraisersDisease-focused nonprofitsCharities
Issues
HealthMental healthDiseases and disorders
Characteristics
Conducts researchFundraising eventsNational levelCommunity engagement / volunteeringGala fundraisersTax deductible donations
General information
Address
PO Box 40307
Austin, TX 78704
Metro area
Austin-Round Rock-Georgetown, TX
County
Travis County, TX
Website URL
cureangelman.org/ 
Phone
(866) 783-0078
IRS details
EIN
26-3160079
Fiscal year end
December
Taxreturn type
Form 990
Year formed
2008
Eligible to receive tax-deductible contributions (Pub 78)
Yes
Categorization
NTEE code, primary
G20: Birth Defects and Genetic Diseases
NAICS code, primary
813212: Health and Disease Research Fundraising Organizations
Parent/child status
Independent
Free account sign-up

Want updates when Foundation for Angelman Syndrome Therapeutics has new information, or want to find more organizations like Foundation for Angelman Syndrome Therapeutics?

Create free Cause IQ account